Drug:
Reaction: ECZEMA
20260101 - 20261231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 26876683 |
US |
1 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 402 | 26877388 |
CL |
71 | 1 |
Septic shock, Gastrointestinal disorder, Septic vasculitis, Streptococcal infection, Eczema, Neurodermatitis, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, PREDNISONE, |
||||
| 403 | 26877483 |
US |
38 | 2 |
Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, LORATADINE, LORATADINE TABLET, EPINEPHRINE, FISH OIL, MOMETASONE FUROATE, MOMETASONE, ERGOCALCIFEROL, |
||||
| 404 | 26878153 |
US |
11 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 405 | 26878179 |
US |
51 | 1 |
Eczema, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 406 | 26878184 |
US |
1 | |
Eczema, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 407 | 26878343 |
CA |
||
Rheumatoid arthritis, Eczema, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, NAPROXEN, NAPROXEN SODIUM, PREDNISONE, |
||||
| 408 | 26878560 |
US |
2 | |
Eczema, Skin irritation, |
||||
DUPILUMAB, |
||||
| 409 | 26879434 |
US |
||
Eczema, |
||||
DUPILUMAB, |
||||
| 410 | 26879439 |
US |
62 | 2 |
Cellulitis, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 411 | 26879468 |
US |
75 | 2 |
Fatigue, Pain, Erythema, Swelling, Ocular hyperaemia, Dry eye, Myalgia, Arthralgia, Eczema, |
||||
DUPILUMAB, DUPILUMAB, OMALIZUMAB, |
||||
| 412 | 26879951 |
US |
25 | 1 |
Dry skin, Eczema, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 413 | 26880514 |
US |
24 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, UPADACITINIB, |
||||
| 414 | 26880541 |
US |
||
Conjunctivitis, Dry eye, Eczema, Product dose omission issue, |
||||
RUXOLITINIB, |
||||
| 415 | 26881028 |
US |
2 | |
Eczema, |
||||
LEBRIKIZUMAB-LBKZ, LEBRIKIZUMAB-LBKZ, |
||||
| 416 | 26875197 |
US |
4 | 2 |
Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 417 | 26875202 |
US |
64 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 418 | 26875262 |
US |
3 | 1 |
Eczema, Pruritus, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 419 | 26875321 |
US |
8 | 1 |
Swelling, Eczema, Injection site swelling, Injection site pallor, Injection site pain, |
||||
DUPILUMAB, CETIRIZINE HCL, CETIRIZINE, FLUTICASONE PROPIONATE, MOMETASONE FUROATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ALBUTEROL SULFATE, ERGOCALCIFEROL, |
||||
| 420 | 26875329 |
US |
41 | 1 |
Dermatitis, Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, CYCLOSPORINE, |
||||
| 421 | 26875335 |
US |
2 | |
Gallbladder operation, Erythema, Eczema, Rash, |
||||
DUPILUMAB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, |
||||
| 422 | 26875364 |
US |
1 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 423 | 26875413 |
US |
15 | 2 |
Eczema, Pruritus, Product dose omission issue, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 424 | 26875465 |
US |
37 | 2 |
Pruritus, Eczema, Product ineffective for unapproved use, |
||||
DUPILUMAB, |
||||
| 425 | 26875470 |
US |
8 | 2 |
Injection site pain, Eczema, |
||||
DUPILUMAB, |
||||
| 426 | 26875503 |
US |
1 | 1 |
Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 427 | 26875507 |
US |
54 | 2 |
Eczema, Rash pruritic, Pain, Blister, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 428 | 26875571 |
US |
29 | 1 |
Injection site pain, Injection site bruising, Skin exfoliation, Pruritus, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 429 | 26875603 |
US |
1 | |
Cardiac failure, Eczema, Sinus disorder, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, TACROLIMUS EXTENDED-RELEASE CAPSULES, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, EZETIMIBE, DAPAGLIFLOZIN, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, METHYLPREDNISOLONE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, VERICIGUAT, |
||||
| 430 | 26875704 |
US |
59 | 1 |
Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 431 | 26875706 |
US |
29 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 432 | 26875708 |
US |
73 | 2 |
Injection site pain, Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 433 | 26875709 |
US |
20 | 1 |
Eczema, Rash, |
||||
DUPILUMAB, |
||||
| 434 | 26875710 |
US |
2 | |
Cough, Eczema, Skin exfoliation, Drug ineffective, |
||||
DUPILUMAB, BIOTIN, CITALOPRAM, CITALOPRAM HYDROBROMIDE, GABAPENTIN, HYDROCHLOROTHIAZIDE, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, PANTOPRAZOLE, SIMVASTATIN, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, ERGOCALCIFEROL, |
||||
| 435 | 26875720 |
US |
72 | 1 |
Skin ulcer, Blister, Eczema, Neurodermatitis, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 436 | 26875726 |
US |
2 | |
Inflammation, Pruritus, Eczema, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, FAMOTIDINE, CARBO MORE, CIMETIDINE, PREDNISONE, |
||||
| 437 | 26873345 |
US |
4 | 2 |
Dry eye, Eczema, Rash macular, |
||||
DUPILUMAB, |
||||
| 438 | 26873362 |
US |
34 | 2 |
Injection site dryness, Injection site pain, Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 439 | 26873409 |
US |
65 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 440 | 26873881 |
US |
63 | 2 |
Eczema, Pruritus, Skin exfoliation, Dry skin, Skin fissures, Sleep disorder due to a general medical condition, Ocular hyperaemia, |
||||
DUPILUMAB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 441 | 26873960 |
US |
62 | 2 |
Ocular hyperaemia, Eye pruritus, Eye irritation, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 442 | 26874050 |
US |
24 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 443 | 26874194 |
US |
51 | 2 |
Headache, Malaise, Eczema, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 444 | 26874199 |
US |
2 | |
Eczema, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 445 | 26874328 |
US |
2 | |
Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 446 | 26874512 |
US |
2 | |
Eczema, Neutrophil count increased, Nasopharyngitis, Headache, Muscle spasms, Nasal congestion, Neutropenia, Nausea, Dizziness, Hepatic function abnormal, Aspartate aminotransferase increased, Diarrhoea, Neutrophil count decreased, |
||||
FOSTAMATINIB, FOSTAMATINIB, FOSTAMATINIB, FOSTAMATINIB, FOSTAMATINIB, |
||||
| 447 | 26874555 |
US |
10 | 1 |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, |
||||
| 448 | 26874724 |
US |
45 | 2 |
Papule, Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 449 | 26874725 |
US |
18 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 450 | 26875024 |
US |
54 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 451 | 26875049 |
US |
43 | 1 |
Eczema, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 452 | 26875053 |
US |
2 | |
Eczema, Injection site pain, Injection site rash, |
||||
DUPILUMAB, IRON, |
||||
| 453 | 26875054 |
US |
11 | 2 |
Infectious mononucleosis, Influenza like illness, Lethargy, Eczema, |
||||
DUPILUMAB, |
||||
| 454 | 26875091 |
US |
6 | 2 |
Eczema, Initial insomnia, |
||||
DUPILUMAB, |
||||
| 455 | 26875099 |
US |
25 | 2 |
Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 456 | 26867969 |
US |
2 | |
Eczema, Gait disturbance, |
||||
DUPILUMAB, ZOLPIDEM TARTRATE, BETAMETHASONE DIPROPIONATE, CALCIUM, FISH OIL, HYDROCHLOROTHIAZIDE, ESCITALOPRAM, MAGNESIUM, RUXOLITINIB, ERGOCALCIFEROL, SIMVASTATIN, |
||||
| 457 | 26867990 |
US |
54 | 2 |
Eczema, Pruritus, Skin warm, Scab, Scar, Sleep disorder, Activities of daily living decreased, Affective disorder, |
||||
DUPILUMAB, MONTELUKAST SODIUM, PREDNISONE, |
||||
| 458 | 26867994 |
US |
44 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 459 | 26868180 |
US |
3 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 460 | 26868402 |
US |
35 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 461 | 26868410 |
US |
15 | 1 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 462 | 26868421 |
US |
1 | |
Dry skin, Pruritus, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 463 | 26868714 |
US |
67 | 1 |
Fatigue, Eczema, Swelling, Skin fissures, Dry skin, Skin exfoliation, Erythema, |
||||
DUPILUMAB, |
||||
| 464 | 26868747 |
US |
19 | 2 |
Abdominal distension, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 465 | 26868751 |
US |
2 | |
Urticaria, Eczema, Pruritus, Drug ineffective, |
||||
DUPILUMAB, ALBUTEROL SULFATE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, SERTRALINE HYDROCHLORIDE, ZONISAMIDE, |
||||
| 466 | 26869115 |
US |
6 | 1 |
Eczema, Erythema, Dry skin, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 467 | 26869673 |
US |
8 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 468 | 26869705 |
US |
1 | |
Asthma, Eczema, |
||||
DUPILUMAB, |
||||
| 469 | 26869853 |
US |
78 | 2 |
Lower respiratory tract infection, Faecaloma, Alopecia, Psoriasis, Dyspnoea, Erythema, Eczema, Influenza, Epistaxis, Cough, Sinus disorder, Headache, Hepatic pain, Weight increased, Constipation, Granuloma, |
||||
INCLISIRAN, INCLISIRAN, |
||||
| 470 | 26870071 |
US |
45 | 1 |
Eczema, Lipids abnormal, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 471 | 26870885 |
US |
16 | 1 |
Eczema, Pruritus, |
||||
DUPILUMAB, |
||||
| 472 | 26870903 |
US |
64 | 2 |
Eczema, Pruritus, Skin haemorrhage, Skin fissures, Skin exfoliation, Dry skin, |
||||
DUPILUMAB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, HYDROCHLOROTHIAZIDE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VALSARTAN, VALSARTAN ORAL, |
||||
| 473 | 26871308 |
US |
9 | 2 |
Eczema, Therapeutic response shortened, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 474 | 26871311 |
US |
22 | 2 |
Eczema, Therapeutic response shortened, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 475 | 26871325 |
US |
4 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 476 | 26871330 |
US |
45 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 477 | 26871339 |
US |
8 | 1 |
Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 478 | 26871348 |
US |
2 | |
Eczema, |
||||
DUPILUMAB, ALBUTEROL SULFATE, CETIRIZINE HYDROCHLORIDE, |
||||
| 479 | 26871679 |
US |
20 | 1 |
Eczema, Product prescribing error, |
||||
DUPILUMAB, |
||||
| 480 | 26871683 |
US |
59 | 2 |
Eczema, Injection site pain, |
||||
DUPILUMAB, |
||||
| 481 | 26871692 |
US |
33 | 1 |
Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 482 | 26871704 |
US |
63 | 2 |
Rash, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 483 | 26872019 |
US |
25 | 1 |
Eczema, Eye swelling, |
||||
DUPILUMAB, |
||||
| 484 | 26872020 |
US |
2 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 485 | 26872283 |
US |
1 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 486 | 26872472 |
US |
2 | |
Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, FEXOFENADINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 487 | 26872478 |
US |
2 | |
Pruritus, Feeling abnormal, Eczema, Sleep disorder, Rash, |
||||
DUPILUMAB, |
||||
| 488 | 26872653 |
62 | 2 | |
Rash, Eczema, Intracranial mass, Brain stent insertion, Brain operation, |
||||
DIROXIMEL FUMARATE, |
||||
| 489 | 26872691 |
US |
53 | 2 |
Eczema, Pruritus, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 490 | 26872692 |
US |
41 | 2 |
Eczema, Intentional dose omission, Rash, Urticaria, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 491 | 26872787 |
US |
35 | 1 |
Syncope, Sensory disturbance, Blood prolactin increased, Liver function test increased, Dyspepsia, Breast discharge, Nipple swelling, Gynaecomastia, Hypoaesthesia, Galactorrhoea, Constipation, Creatine kinase increased, Eczema, COVID-19, Illness, Stomatitis, Rash, Diarrhoea, Cyst, Stress fracture, Lower limb fracture, Abdominal pain, Arthralgia, Pain in extremity, Product dose omission issue, Insurance issue, |
||||
NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, NIROGACESTAT, |
||||
| 492 | 26862651 |
US |
5 | 1 |
Eczema, Pruritus, |
||||
DUPILUMAB, |
||||
| 493 | 26862848 |
US |
40 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 494 | 26863100 |
US |
14 | 1 |
Injury associated with device, Eczema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 495 | 26863274 |
US |
80 | 2 |
Nasal congestion, Eczema, Nasal obstruction, Paranasal sinus discomfort, Pain, Anosmia, Ageusia, Pruritus, Rash, |
||||
DUPILUMAB, |
||||
| 496 | 26863603 |
US |
1 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 497 | 26863608 |
US |
65 | 2 |
Conjunctivitis, Eczema, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 498 | 26863618 |
US |
2 | |
Eczema, Erythema, |
||||
DUPILUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 499 | 26863645 |
US |
1 | |
Eczema, |
||||
DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, CHLORTHALIDONE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, MOMETASONE FUROATE, MOMETASONE, |
||||
| 500 | 26863866 |
US |
2 | |
Rash erythematous, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30